Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fluconazole on the Pharmacokinetics of Olomorasib in Healthy Participants
NCT07439250Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olomorasib in solid tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve at Day 12 and Maximum Concentration at Day 12. Started Mar 2026; status: completed.
02
Drugs
olomorasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07439250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439250.